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Abstract
Background: The emergence of neuraminidase inhibitor resistance has raised concerns about the prudent use of antiviral
drugs in response to the next influenza pandemic. While resistant strains may initially emerge with compromised viral
fitness, mutations that largely compensate for this impaired fitness can arise. Understanding the extent to which these
mutations affect the spread of disease in the population can have important implications for developing pandemic plans.
Methodology/Principal Findings: By employing a deterministic mathematical model, we investigate possible scenarios for
the emergence of population-wide resistance in the presence of antiviral drugs. The results show that if the treatment level
(the fraction of clinical infections which receives treatment) is maintained constant during the course of the outbreak, there
is an optimal level that minimizes the final size of the pandemic. However, aggressive treatment above the optimal level can
substantially promote the spread of highly transmissible resistant mutants and increase the total number of infections. We
demonstrate that resistant outbreaks can occur more readily when the spread of disease is further delayed by applying
other curtailing measures, even if treatment levels are kept modest. However, by changing treatment levels over the course
of the pandemic, it is possible to reduce the final size of the pandemic below the minimum achieved at the optimal
constant level. This reduction can occur with low treatment levels during the early stages of the pandemic, followed by a
sharp increase in drug-use before the virus becomes widely spread.
Conclusions/Significance: Our findings suggest that an adaptive antiviral strategy with conservative initial treatment levels,
followed by a timely increase in the scale of drug-use, can minimize the final size of a pandemic while preventing large
outbreaks of resistant infections.
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Introduction
The use of antiviral drugs to mitigate the impact of a nascent
influenza pandemic has been evaluated in several recent modelling
studies [1–7], with significant public health implications for
identifying effective preparedness strategies. These studies suggest
that early diagnosis and prompt onset of treatment of clinical cases
is crucial for possible containment of a pandemic. A key
assumption is that the virus remains less transmissible than
pandemic viruses of the last century, so that the reproduction
number of disease transmission stays below 1.8 [1,6,7]. However,
the effectiveness of antiviral drugs may be diminished by several
factors, including a delay in start of treatment, and more
importantly, the emergence and transmission of drug-resistant
viral mutants in the population [8–12].
While antiviral therapy appears to be central in any containment
strategy,itwillimpactthe emergenceofdrug-resistance in a complex
manner. On one hand, early application of antiviral drugs will
largely inhibit generation of resistant viruses by suppressing viral
replication.Ontheotherhand,itresultsina longertime forselection
in favour of pre-existing resistant mutants to restore their impaired
replication fitness through compensatory mutations [13,14]. With
sufficiently increased fitness, resistant viruses may gain a competitive
advantage in the spread of infection and establish a self-sustaining
epidemicofviralresistance[8,9,14].Strategicuseofantiviraldrugsis
therefore crucial for not only mitigating the impact of the wild-type
strain, but also preventing the occurrence of pandemic waves of
drug-resistant infections.
The dynamics of competition between the wild-type and
resistant strains is in general complex. If treatment is poorly
administered, then the wild-type strain spreads rapidly and
depletes the pool of susceptibles in the population, which would
afford little chance for resistant strains to evolve or cause an
outbreak of drug-resistance [8,9]. It has been suggested that
intensive antiviral treatment may eliminate the wild-type infection
(when transmission of the virus is largely interrupted) without
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1839promoting the spread of resistant strains if transmissibility of
resistant strains is sufficiently low [9]. Regardless of the feasibility
of such antiviral strategy, high treatment levels can exert strong
selective pressures that confer resistance that frequently evolves far
more rapidly than the natural rate. The evolution of such mutants
is influenced by several factors, including the duration of
treatment, the delay in onset of therapy, and the rate at which
de novo resistant mutations occur [8]. Combined with compen-
satory mutations that raise fitness of resistant viruses [13,14],
intensive treatment may indeed result in a devastating pandemic of
resistant viral mutants. Understanding the dynamics of the
emergence of drug-resistance is therefore crucial for implementa-
tion of effective mitigation strategies.
In this paper, we extend previous work [8,15] to illustrate the
possible scenarios of disease outbreak in the population, including
single-strain infections and co-existence of wild-type and resistant
infections. By incorporating compensatory mutations into a
mathematical model, we discuss the role of the transmission
fitness of resistant mutants in determining the outcomes of
antiviral strategies with constant and varying treatment levels. In
the following, we describe the model based on the existing
frameworks [8,15], and provide details of the equations and
analysis in ‘‘Text S1’’. We derive the control reproduction number
of the wild-type strain and use it for delineating the results and
their epidemiological consequences for the strategic use of antiviral
drugs in response to a future pandemic.
Methods
The model
To develop a population dynamical model, we followed
previous work [8,15] and divided the population into several
compartments comprising susceptible, exposed, asymptomatic,
and symptomatic infected individuals. In our model, exposed
individuals undergo a latent period, during which viral titers
increase to detectable and transmissible levels [16]. An exposed
individual may become infectious after the latent period and shed
virus without showing clinical symptoms; this is referred to as
asymptomatic infection. Considering the kinetics of influenza
infection in humans [16], we divided the clinical course of
infection into three stages: (i) pre-symptomatic infection, (ii)
primary stage of symptomatic infection (referred to as the window
of opportunity for start of treatment); and (iii) secondary stage of
symptomatic infection (Figure 1). The relative transmissibility of
the virus at each stage is estimated by superposing a step-function
on the log-normal curve fitted to household longitudinal data on
influenza viral shedding [1,17]. Antiviral treatment, as a single
containment strategy, may be initiated upon diagnosis of a clinical
casewithin the window of opportunity; however, those who have not
started treatment in this window will receive no antiviral therapy
duringthesecondarystageofsymptomaticinfection.Theprobability
of an individual receiving treatment decreases with the time elapsed
since the onset of symptoms, whichis reflected inthe functional form
of the treatment rate with delay in seeking healthcare [8,15]. We
assumed that treatment reduces the infectiousness level of the wild-
type disease by 60% (reflected as a reduced transmission rate in the
model since initiation of treatment), but has no effect on individuals
infected with resistant viruses.
We considered a two-day window of opportunity for initiating
treatment of indexed cases following the onset of clinical disease. It
is assumed that resistant mutants with low transmission fitness (dr)
emerge during treatment of individuals infected with the wild-type
strain. With continuous replication of the virus, the rate of
developing de-novo resistance is greatest when treatment is started
near the peak of viral titers [8]. Although resistant mutants may
initially emerge with compromised fitness and growth [18],
mutations that compensate for this impaired fitness may arise
[13,14]. These compensatory mutations can generate variants with
Figure 1. Model structure for the emergence of drug-resistance during treatment of symptomatic infections. The clinical course of
disease is divided into three stages: pre-symptomatic; primary; and secondary stages of symptomatic infections. Drug-resistance with low
transmission fitness can emerge during treatment of individuals infected with the wild-type virus. It is assumed that compensatory mutations may
result in generation of resistant mutants with high transmission fitness during the secondary stage of treated symptomatic infection. The
compartments of untreated and treated individuals infected with the wild-type strain are represented by IU and IT, respectively. The corresponding
compartments for the resistant strain with low (high) transmission fitness are denoted by sub-index r (rH).
doi:10.1371/journal.pone.0001839.g001
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strain. Such mutations are more likely to occur during the
secondary stage of symptomatic infection, as resistant mutants in
viruses isolated from treated patients were mostly detected 3 days
after the onset of treatment [19,20]. We extended the model to
include compartments of individuals who are carriers of highly
transmissible resistant viruses (either evolved during treatment or
transmitted through direct person-to-person contacts) in both
asymptomatic and symptomatic infection. We incorporated
parameters for the treatment and emergence of drug-resistance
(Table 1) into a deterministic epidemic model formulated by a
system of delay differential equations (see ‘‘Text S1’’).
Reproduction numbers
In order to evaluate the effect of parameters described in Table 1
on disease propagation, we calculated the control reproduction
number of the wild-type strain (Rw
c ), as a function of treatment
level and delay in onset of therapy. In the absence of treatment,
the quantity Rw
c reduces to the basic reproduction number (Rw
0),
defined as the number of new infections generated by a single
infected case introduced into a wholly susceptible population [21],
and given by
Rw
0~bS0
1{p ðÞ dA
mA
z
pdU
mUzdU
zpdPtzpn {t ðÞ

,
where b is the baseline transmission rate of the wild-type virus; S0
is the size of the susceptible population at the onset of pandemic; p
represents the probability of developing clinical disease; mA and mU
are, respectively, the recovery rate of asymptomatic and symptom-
atic infections (secondary stage); dA, dP,a n ddU represent the relative
transmissibility of the virus during asymptomatic, pre-symptomatic,
and secondary stage of symptomatic infections; dU is the disease-
induced death rate; t is the period of pre-symptomatic infection; and
n represents the period of the primary stage of symptomatic infection
(see Table 1 in ‘‘Text S1’’). We also derived the expressions for the
number of new infections generated through direct transmission of
resistant viruses with low fitness (Rr
0) and high fitness (RrH
0 ), and
obtained a criterion for the control of disease (see ‘‘Text S1’’).
Results
We considered the scenario in which a novel transmissible
pandemic virus arises (at time t=0) in a susceptible population of
size S0=100 000 with no pre-existing immunity. We assumed that
the treatment of indexed cases begins one day after the onset of
clinical disease. The rate of de novo resistance (aT) that generates
mutants with low fitness ranges from 0.018 to 0.072 day
21
[11,12], and we assumed a baseline value of aT=0.018 day
21.I n
our model, this rate results in the emergence of drug-resistance in
approximately 4.8% of treated patients during secondary stage of
symptomatic infection, with very marginal dependence on
treatment level. We used the same rate for resistance emergence
in the primary stage of symptomatic infection, which allows for the
development of approximately 1% resistant infections during the
primary stage of symptomatic infection. These rates contribute to
an overall (approximately) 5.8% resistance emergence, which lies
within the estimated range 1%–18% incidence of neuraminidase
resistance reported in clinical samples [18,19,20].
We assumed that the fraction of treated individuals (hosting
resistant viruses with low fitness) which undergoes compensatory
mutations and subsequently generates resistant strains with high
fitness lies between 1/5000 and 1/500 [9]. This is 10-fold greater
than the corresponding fraction of untreated resistant cases [14].
We used these fractions to determine the ranges of conversion
rates between low and high fitness resistant strains. To illustrate
the typical outbreaks of wild-type and resistant infections, we
inserted the following parameter values: cT=0.0036 day
21;
cU=0.00036 day
21; dr=0.2; drH=0.9; which correspond to
probability 5610
24 that a treated individual infected with the
wild-type virus develops drug-resistance with high transmission
fitness. Baseline values of these parameters and their respective
ranges used for simulations and sensitivity analyses are given in
Table 1, and details are provided in ‘‘Text S1’’.
Constant treatment strategy
Assuming Rw
0~1:6 and RrH
0 ~1:44, Figure 2 shows the
occurrence of disease outbreaks for constant treatment levels
during the entire course of the pandemic. For 50% treatment level
of clinical cases, the wild-type strain spreads quickly and depletes
the susceptible population, and therefore a limited number of
resistant cases is generated (Figure 2a). Increasing treatment level
to 78% leads to a reduction in the clinical attack rate of the wild-
type virus from 22% (at 50% treatment level) to 16%, and lowers
Rw
c from 1.38 to 1.25 (Figure 2b). In this case, however, the
emergent resistant mutants begin to invade the susceptible hosts
and establish a self-sustaining epidemic. Further increase in the
treatment level to 90% enhances the spread of resistant mutants
and leads to the co-existence of outbreaks (Figure 2c). With higher
treatment level (95%), Rw
c is reduced considerably below RrH
0 , and
the resistant outbreak substantially dominates that of the wild-type
strain (Figure 2d). Transmission of wild-type infections is
Table 1. Description of transmission, mutation, and treatment parameters of the model with their baseline values and ranges used
for simulations and sensitivity analyses.
Symbol Description Value (Range) Reference
dr relative transmissibility of resistant strain with low fitness 0.2 (,0.4) [8,9,11]
drH relative transmissibility of resistant strain with high fitness variable (.0.6) [8,9,11]
rmax maximum rate of emergence of drug-resistance within the window of opportunity 0.018 (0.018–0.072) day
21 [11,12]
aT rate of emergence of drug-resistance during secondary stage of symptomatic infection 0.018 (0.018–0.072) day
21 [11,12]
cU rate of conversion between resistant mutants in untreated symptomatic infection 3.6610
24 (10
26–10
21) day
21 [14]
cT rate of conversion between resistant mutants in treated symptomatic infection 3.6610
23 (10
26–10
21) day
21 [14]
12q fraction of infected individuals which receives treatment (treatment level) variable (0–1) 2
Rw
0 reproduction number of the wild-type strain 1.6 (1.4–2) [1,2,4,6,7]
doi:10.1371/journal.pone.0001839.t001
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However, the wide-spread presence of resistant strains results in a
higher overall attack rate than would have been the case if
treatment were administered at a lower rate. We observed similar
patterns for outbreaks of wild-type and resistant infections with
higher values of Rw
0. However, in these cases, wide-spread drug-
resistance is less probable and requires higher levels of treatment to
significantly interrupt the transmission of wild-type infections.
Although the use of antiviral drugs appears to be essential for
combating the wild-type strain, it can potentially lead to the
population-wide spread of drug-resistance. To demonstrate the
interplay between these opposing effects, we simulated the model
to determine the final size of the epidemic, using Rw
0~1:6 and
Rw
0~1:8, as a function of treatment level. The solid curves in
Figures 3a–b show the total number of clinical infections and
deaths during the entire course of an outbreak. As is evident,
increasing the treatment level decreases the overall number of
infections to a minimum, beyond which the compensated resistant
mutants gain a competitive advantage and spread widely through
the population (Figure 3d), thereby increasing the final size of the
outbreak. The treatment level at which this minimum is achieved
will be referred to as the optimal constant level. Although this
pattern is qualitatively preserved for different reproduction
numbers, the optimal treatment level is lower for smaller Rw
0
(Figure 3a), and therefore the outbreaks of drug-resistant infections
become more likely even with moderate treatment levels. This
suggests that reducing Rw
0 through application of other mitigation
strategies may compromise the overall impact of antiviral therapy
[9], should compensated mutants emerge (Figure 3d). However, in
the absence of compensatory mutations, increasing treatment level
would continue to decrease the epidemic size (Figure 3a, dashed
curves), as resistant strains exist only at significantly lower
Figure 2. Time-courses of clinical infections with one day delay in onset of treatment of indexed cases, with Rw
0~1:6. Simulations were
run, when a single case infected with the wild-type virus is introduced into the susceptible population of size S0=100 000. Treatment levels are: (a)
50%; (b) 78%; (c) 90%; and (d) 95%. The corresponding reproduction numbers of the wild-type strain are: (a) Rw
c ~1:38; (b) Rw
c ~1:25; (c) Rw
c ~1:18;
and (d) Rw
c ~1:15.
doi:10.1371/journal.pone.0001839.g002
Figure3.(a)Totalnumber ofclinicalinfectionscausedbythewild-type, lowfitnessresistant,andhighfitnessresistantstrains;(b) Totalnumberofdeaths;
(c) Total number of clinical infections caused by the low fitness resistant strains; (d) Total number of clinical infections caused by the high fitnessr e s i s t a n t
strains, as a function of treatment level. Treatment of infected individuals begins one day after the onset of clinical disease; red and black curves
correspond, respectively, to the reproduction numbers Rw
0~1:6 (Rr
0~0:32, RrH
0 ~1:44)a n dRw
0~1:8 (Rr
0~0:36, RrH
0 ~1:62). Dashed curves in (a) and (b)
correspond to the scenario in which no compensatory mutations occur, and resistant mutants are only present at low fitness cost.
doi:10.1371/journal.pone.0001839.g003
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importantly, the optimal level reduces as transmission fitness of the
resistant strain exceeds a certain threshold and increases towards
that of the wild-type virus. To demonstrate this, we performed
sensitivity analyses over a range of key parameters, including the
basic reproduction number of wild-type virus, the rates of de novo
resistance, and the rates of conversion between resistant strains (see
‘‘Text S1’’). Figure 4 displays the results of variations in the
optimal treatment level as a function of drH. Although qualitatively
similar results were obtained through a simple compartmental
model [9], the integration of different stages of disease at the
individual level and the likely delay in seeking healthcare and
therefore initiating therapy, can have important consequences for
developing pandemic plans [8].
Adaptive treatment strategy
In the event of emerging drug-resistance, it has been suggested
[1] that reducing treatment levels may permit the wild-type to
outcompete the resistant strains due to its greater fitness, thereby
preventing large resistant outbreaks. To investigate this strategy,
we modified the model to allow for changing the population2level
of treatment at a specified time (t
*) during a pandemic. We define
T as the total number of clinical infections when an antiviral
strategy with varying level of treatment is implemented, and let Tc
be the total number of clinical infections when treatment is
maintained at the optimal constant level. The ratio T/Tc provides
a criterion for identifying effective strategies for controlling the
spread of disease. Assuming Rw
0~1:6, we simulated the model
when antiviral treatment is initiated at an 85% level (above the
corresponding optimal constant level 78%). The results show that
the final size of infections may be reduced only if treatment is
scaled down to the optimal level during the early stages of the
pandemic (Figures 5a), before outbreaks of compensated mutants
can occur (Figure 6a). Further simulations (Figure 5b) with a 78%
initial treatment level indicate that reducing antiviral use, at any
time during a pandemic, below the optimal level would increase
the number of clinical infections (T/Tc.1), suggesting that
antiviral therapy at the optimal constant level will be more
effective in mitigating a pandemic, and preventing resistant
outbreaks (Figure 6b). However, the final size of a pandemic
may be slightly reduced if the supply of drugs can afford a
significant increase in the level of treatment at a later stage during
the outbreak.
To further investigate the effect of raising treatment level, we
simulated the model when treatment is initially administered at
25% and 50% (below the optimal level). The results show a
significant reduction in the total number of clinical infections
compared with that achieved at the optimal constant level
(Figure 5c,d). However, the effectiveness of this strategy depends
critically on the initial scale of drug-use and the time at which the
level of treatment is raised. As is evident from Figure 5d, for lower
treatment levels, an earlier increase in antiviral use is required for
achieving the minimum final size. This is due to the fact that the
wild-type virus spreads more rapidly (and therefore depletes the
pool of susceptible individuals more quickly) during the initial low
treatment phase. The findings suggest that the impact of this
strategy is much more pronounced in mitigating a pandemic than
a constant treatment plan, even if treatment can be maintained at
the optimal level throughout the entire course of an outbreak.
Figures 6c and 6d indicate that a timely increase in the level of
drug-use can also prevent large outbreaks caused by the
emergence of highly transmissible resistant viruses.
To further exemplify the overall benefit of this strategy, we
simulated the time-courses of infection for two scenarios in which
Figure 4. Sensitivity analysis showing box plots for the
variations in the optimal constant treatment level (below
90%) as a function of drH, with other parameters sampled from
their respective ranges, as described in ‘‘Text S1’’. The solid
curve passes through the median values of the treatment level, and
each box contains 50% of data points between the first and third
quartiles of the sampling distribution. The remaining 50% of data points
are represented by whiskers.
doi:10.1371/journal.pone.0001839.g004
Figure 5. The effect of changing treatment level during a pandemic on the total number of clinical infections caused by all strains,
with Rw
0~1:6. Simulations were seeded with an initial treatment level of (a) 85%; (b) 78% (optimal level); (c) 50%; (d) 25%, and then changed to the
level shown on the horizontal axis at the time displayed on the vertical axis (corresponding to the time-course of the epidemic). The color bars
illustrate the total number of clinical cases due to all strains, relative to that generated when the optimal constant treatment level (78% in this case) is
implemented.
doi:10.1371/journal.pone.0001839.g005
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at all times during the outbreak (Figure 7a); (ii) treatment is
initiated at a 25% level for the first 50 days, and then increased to
90% for the rest of the outbreak (Figure 7b). In the second
scenario, not only are clinical infections reduced, but also the
spread of highly transmissible resistant viruses is prevented. In this
scenario, the duration of the outbreak is shortened, with an earlier
peak of infection. Compared with Figure 2c, in which treatment is
kept at 90% from the beginning of the outbreak, it is observed that
conservative treatment levels early on in a pandemic may be
crucial in controlling the spread of resistant viruses. We also
observed that even if the treatment level is only increased to 78%
at day 50, from the initial 25% level, the small outbreak of the
highly transmissible resistant strain shown in Figure 6a can be
prevented, while the total number of clinical infections is also
slightly reduced. Our sensitivity analyses, detailed in ‘‘Text S1’’,
show that these results remain robust across wide ranges of
parameters that govern de novo resistance, compensatory
mutations, and transmissibility of wild-type and resistant strains.
Discussion
In this study, we extended a previous model for the emergence
of drug-resistance [8] to evaluate the likely evolutionary-epidemi-
ological outcomes of an antiviral treatment strategy. We discussed
the influence of three major factors on the population-wide spread
of drug-resistance, namely: (i) the reproduction number of the
wild-type strain; (ii) time-dependent antiviral treatment level; and
(iii) compensatory mutations that raise the replication fitness of
resistant strains.
Our results show that, in the absence of compensatory mutations,
resistant strains with large fitness cost cannot gain a competitive
advantage in the spread of disease, and therefore increasing the level
of antiviral treatment would reduce the final size of the pandemic
(Figure3a,dashedcurves).Whileintensivedrugusemayincreasethe
number of emergent resistant cases during treatment [8,9], the
population incidence of drug-resistance is still limited due to a
significantly lower reproduction number (transmission fitness) of
resistant strains compared with the wild-type virus.
In the presence of compensatory mutations, however, the
competitive interference between wild-type and resistant strains is
more complex. Since transmission fitness of compensated mutants
is generally lower than that of the wild-type virus, the spread of
disease is reduced by increasing drug use to moderate levels
(Figure 3a, solid curves). While the number of emergent resistant
cases increases with higher treatment levels (Figure 3c), the overall
decrease in epidemic size is due to a more pronounced reduction
of the wild-type transmission. As the use of antiviral drugs exceeds
the optimal level, the overall epidemic size begins to grow, since
the reproduction number of compensated mutants now stands well
above that of the wild-type virus. Such wide-spread use of drugs
will largely block transmission of the wild-type infection and
greatly enhance the spread of drug-resistant viral mutants
(Figure 3d), which in turn will increase the final size of the
pandemic (Figure 3a, solid curve). Time courses of wild-type and
resistant infections in Figure 2 illustrate these dramatic changes in
the profile of outbreaks for a particular value of the reproduction
number Rw
0~1:6. We observed similar behaviour for Rw
0~1:8
(Figure 3, black curves); however, the population-wide spread of
drug-resistance requires more aggressive use of antiviral drugs.
While it is tempting to prescribe a high level of treatment at the
onset of a pandemic for possible elimination of the wild-type virus,
our simulations show that if aggressive treatment fails to contain
the disease, then large outbreaks of resistant strains can develop.
Considering a range of clinical attack rates above 25%, we have
previously shown that an antiviral treatment as a single
containment strategy will be unsuccessful at controlling the spread
of wild-type disease if Rw
0 exceeds 1.4 [8]. Our findings in this
study suggest that, as an alternative strategy, conservative
treatment levels during the early stages of an outbreak can
Figure 6. The effect of changing treatment level during a pandemic on the total number of clinical infections caused by the high
fitness resistant strain, with Rw
0~1:6. Simulations were seeded with an initial treatment level of (a) 85%; (b) 78% (optimal level); (c) 50%; (d) 25%,
and then changed to the level shown on the horizontal axis at the time displayed on the vertical axis (corresponding to the time-course of the
epidemic). The color bars illustrate the total number of clinical infections due to the resistant strain with high transmission fitness, relative to that
generated when the optimal constant treatment level (78% in this case) is implemented.
doi:10.1371/journal.pone.0001839.g006
Figure 7. Time-courses of clinical infections with one day delay
in onset of treatment of indexed cases for Rw
0~1:6. Simulations
were run, when a single case infected with the wild-type virus is
introduced into the susceptible population of size S0=100 000.
Treatment in (a) is maintained at the optimal level (78%) for the entire
course of the outbreak. Treatment in (b) is initiated at a 25% level for
the first 50 days (shaded area), and then increased to 90% for the rest of
the outbreak. All other parameters are the same as those used for
simulations in Figure 2.
doi:10.1371/journal.pone.0001839.g007
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If followed by a timely increase in the level of drug-use, this
strategy would preserve the potential for minimizing the final size
of a pandemic (Figures 5c,d), while preventing large outbreaks of
resistant viruses (Figures 6c,d). The principal mechanism under-
lying this adaptive antiviral strategy is to sufficiently reduce the
number of susceptible individuals through an initial growth of
wild-type infection, which will in turn prevent outbreaks of drug-
resistant infections. However, an initial high treatment level
followed by a reduction in antiviral use due to shortage in drug
supply or emergence of highly transmissible drug-resistant strains
in the population appears to be a poor strategy for disease control.
We tested the robustness of our findings by performing sensitivity
analyses over the estimated ranges of parameters describing the
transmissibility of wild-type and resistant strains, de novo
resistance emergence, and compensatory mutations that raise the
fitness of resistant mutants. We also employed a previous
population dynamical model for the emergence and spread of
drug-resistance [9], and observed qualitatively consistent results
for the proposed antiviral strategy. The findings of this study
clearly indicate that any containment policy should be integrated
with surveillance and monitoring systems, so that necessary
adaptations to the treatment strategy can be made in a timely
fashion, should resistant mutants with high transmission fitness
emerge during the pandemic.
The modelling efforts in this study aim to evaluate the possible
outcomes of various antiviral strategies. The work is meant to be a
proof of concept rather than to provide specific quantitative
recommendations for treatment policies, and we therefore
emphasize the qualitative aspects of this evaluation. Nevertheless
our evaluation, together with its sensitivity analyses, suggest that
delaying implementation of aggressive treatment would reduce the
overall disease burden, and significantly lower the probability of
resistant outbreaks occurring. This strategy may be particularly
beneficial when considering scarce resources of antiviral drugs,
limited production capacity, and the surge in demand for
treatment with the progression of a pandemic. Historical
precedent, from both seasonal influenza epidemics and the
1918–1919 influenza pandemic, suggests that a novel influenza
strain with high pathogenicity would severely tax existing health
resources, and would force healthcare administrators and
providers alike to make difficult decisions that may include
rationing of scarce resources (e.g., antiviral drugs). Comparison of
the potential consequences of competing strategies, as well as the
practices required to achieve best outcomes, will allow for optimal
resource allocation and health policy decisions.
For the results reported here, we assumed that antiviral drugs
are used for treatment of only indexed cases having the same
estimated efficacy of application as during interpandemic
influenza outbreaks. However, the effect of antiviral therapy on
the development of drug-resistance is much more pronounced
when prophylactic use of drugs is planned in addition to
treatment, as discussed in recent studies [9,11]. Our simulations
are based on parameters extracted from the published literature,
and involve some degree of uncertainty, particularly with regard to
the parameters that govern de novo resistance emergence and
compensatory mutations. While highlighting the qualitative
aspects of our study, parameter estimates from in vivo data
associated with resistant mutations are needed to provide more
accurate quantitative predictions. Combined with the previous
work [8] that integrates the latest insights concerning within-host
viral dynamics with the between-host spread of disease, a
predictive framework of the emergence of drug-resistance is now
on the horizon.
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